BharatNotes Health Biotechnology — Overview
Health biotechnology (Red Biotechnology) applies biological systems to diagnose, prevent, and treat disease. For India, it sits at the intersection of strategic capability, public health equity, and global economic influence.
India supplies over 20% of global generic medicines by volume and accounts for more than 60% of global vaccine demand. This "pharmacy of the world" status rests on three pillars: a vast, cost-competitive manufacturing base; decades of public R&D investment; and a large, diverse patient population that makes India an ideal clinical-research hub.
Pharma exports reached USD 30.47 billion in FY 2024–25, registering 9.4% year-on-year growth (PHARMEXCIL data). The United States absorbs ~34% of exports, Europe ~19%, and the remainder is spread across over 200 markets.
India's Vaccine Industry
The Big Three Manufacturers
| Manufacturer | Headquarters | Key Vaccines / Products | Scale |
|---|---|---|---|
| Serum Institute of India (SII) | Pune | COVISHIELD (AstraZeneca), CERVAVAC (HPV), pentavalent, MMR, polio, influenza | World's largest by doses; >1.5 billion doses/year capacity; vaccines used in ~170 countries |
| Bharat Biotech | Hyderabad (Genome Valley) | Covaxin (BBV152), ROTAVAC, JENVAC (JE), Hillchol (cholera), rabies, chikungunya | >9 billion doses delivered globally; 19+ vaccines; WHO prequalification for multiple products |
| Biological E. Limited | Hyderabad | Corbevax (COVID-19), pentavalent DPT-HepB-Hib, Hib vaccine | Oldest private biologics firm (est. 1953); supplies >130 countries |
Key fact: About 65% of children in the world receive at least one vaccine manufactured by Serum Institute of India.
Why India Dominates Global Vaccine Supply
- Cost advantage: Manufacturing costs 60–80% lower than Western competitors due to labour, scale, and API access.
- WHO-prequalified facilities: Multiple plants qualify for UNICEF and Gavi procurement.
- Mission COVID Suraksha (2020–21): DBT mission that co-funded indigenous COVID vaccine development — accelerated both Covaxin and the Corbevax supply chain.
- BIRAC support: Biotechnology Industry Research Assistance Council (BIRAC) provides grants, equity funding, and technology transfer support to vaccine start-ups.
Types of Vaccines — Mechanism Comparison
| Type | Mechanism | Examples | Advantages |
|---|---|---|---|
| Live Attenuated | Weakened pathogen induces strong immune response | MMR, OPV (oral polio), BCG, chickenpox | Long-lasting immunity; often single dose |
| Inactivated / Killed | Killed pathogen; cannot replicate | Covaxin (BBV152), IPV, Hepatitis A | Stable; no risk of reversion |
| Subunit / Protein | Purified antigen (e.g., surface protein) | Corbevax (RBD protein), Hepatitis B, CERVAVAC (HPV VLP) | Highly safe; no live pathogen |
| mRNA | mRNA instructs cells to make antigen; no DNA entry into nucleus | Pfizer-BioNTech (BNT162b2), Moderna (mRNA-1273) | Rapid design; adaptable; no live pathogen |
| Viral Vector | Non-replicating virus delivers antigen gene | COVISHIELD (ChAdOx1), Sputnik V, J&J | Potent cellular immunity |
| Toxoid | Inactivated bacterial toxin | Tetanus, Diphtheria | Targets toxin, not bacterium |
mRNA Vaccine Technology
How mRNA Vaccines Work
- A synthetic messenger RNA (mRNA) strand — encoding the target antigen (e.g., spike protein) — is packaged in lipid nanoparticles (LNPs).
- LNPs fuse with cell membranes and deliver mRNA into the cytoplasm (not the nucleus; no DNA integration).
- Ribosomes translate mRNA → antigen protein is displayed on the cell surface.
- The immune system recognises it as foreign, generates antibodies and memory T/B cells.
- mRNA degrades within days; no permanent genetic trace.
Global mRNA Leaders
| Vaccine | Developer | Platform | Notable Feature |
|---|---|---|---|
| BNT162b2 (Comirnaty) | Pfizer–BioNTech | Conventional mRNA / LNP | First mRNA vaccine to receive full FDA approval |
| mRNA-1273 (Spikevax) | Moderna | Conventional mRNA / LNP | Higher dose; superior cold-chain stability |
| HGCO19 | Gennova (India) + HDT Bio (USA) | Self-amplifying mRNA (saRNA) | Lyophilised — less stringent cold-chain; smaller dose needed |
India's mRNA Vaccine Development
Gennova Biopharmaceuticals (Pune, subsidiary of Emcure), in partnership with HDT Bio Corp (USA), developed HGCO19 — India's first indigenous mRNA vaccine candidate for COVID-19, funded by DBT under Mission COVID Suraksha.
Key differentiator: Gennova's platform uses self-amplifying mRNA (saRNA) — the RNA encodes its own replication machinery, so a much smaller dose achieves the same immune response. This is particularly suited to low- and middle-income countries where cold-chain logistics are a challenge.
In 2025, Gennova received expanded CEPI funding (up to USD 13.38 million) to develop a saRNA vaccine against Nipah virus — demonstrating that India's mRNA platform has moved beyond COVID-19.
Exam tip: mRNA vaccines do NOT alter DNA. The mRNA never enters the nucleus. This is a frequent Prelims distractor.
CERVAVAC — India's Indigenous HPV Vaccine
| Parameter | Detail |
|---|---|
| Full name | Quadrivalent Human Papillomavirus (qHPV) Vaccine (Serotypes 6, 11, 16, 18) |
| Developer | Serum Institute of India (SII) |
| Launched | 24 January 2023 (National Girl Child Day) |
| Type | Virus-Like Particle (VLP) subunit vaccine |
| Partners | DBT + BIRAC + Bill and Melinda Gates Foundation |
| Production capacity | 70 million doses/year; target 140 million doses by 2026 |
| Price | Affordable, intended to undercut imported HPV vaccines (Gardasil, Cervarix cost ₹2,500–4,000/dose commercially) |
| WHO status | Seeking WHO prequalification (as of 2024) |
| Significance | India accounts for ~25% of global cervical cancer deaths; cervical cancer is the 2nd most common cancer in Indian women |
Context: India launched a nationwide HPV vaccination programme for girls aged 9–14 years under the Universal Immunisation Programme (UIP). CERVAVAC's domestic availability was critical for this rollout.
Covaxin (BBV152) — India's First Indigenous COVID Vaccine
| Parameter | Detail |
|---|---|
| Developer | Bharat Biotech International Limited (BBIL) |
| Type | Whole-virion inactivated COVID-19 vaccine; Vero cell platform |
| Platform partner | ICMR (Indian Council of Medical Research) — NIV Pune provided the virus strain |
| DCGI approval | Emergency Use Authorisation — 3 January 2021 |
| WHO EUL | Granted 3 November 2021 |
| Manufacturing concern | WHO suspended UN procurement supply in April 2022 due to GMP deficiencies; Bharat Biotech suspended export production to address these |
| Doses administered | Over 77 million doses in India |
| Licensed in | 23+ countries |
| Adjuvant | Algel-IMDG (imidazoquinoline molecule) — a Toll-Like Receptor 7/8 agonist that boosts innate immunity |
Covaxin's significance: First COVID vaccine globally based on a whole-virion inactivated platform to receive WHO EUL; developed in record 18 months from concept to approval; demonstrated the potential of ICMR–private sector collaboration.
GenomeIndia Project
Overview
| Parameter | Detail |
|---|---|
| Launched | 2020 — announced by PM Modi; funded by Department of Biotechnology (DBT) |
| Lead institution | Centre for Brain Research, Indian Institute of Science (IISc), Bengaluru |
| Consortium | 20 academic and research institutions across India |
| Milestone | Sequencing of 10,074 whole genomes completed — announced 27 February 2024 |
| Population coverage | 99 diverse communities; 85 distinct population groups (32 tribal + 53 non-tribal); all major linguistic and social groups |
| Variants identified | ~180 million genetic variants (including 130 million on autosomes, 50 million on sex chromosomes); over 135 million variations identified as common and rare variants unique to Indian subgroups |
| Data size | ~8 petabytes |
| Data repository | Indian Biological Data Centre (IBDC), Faridabad — India's first national life-science data repository |
Key Findings and Applications
- Large proportion of identified variants are unique to South Asian or Indian sub-populations — not found in global reference databases (HapMap, 1000 Genomes Project).
- Enables development of India-specific polygenic risk scores for diseases such as type 2 diabetes, cardiovascular disease, and psychiatric disorders.
- Foundation for precision medicine tailored to India's genetic diversity.
- Data is accessible to Indian and global researchers via IBDC portals (Framework for Exchange of Data — FeED protocol launched alongside the data release).
Prelims fact: GenomeIndia's data is stored at IBDC in Faridabad, established by DBT at the Regional Centre for Biotechnology (RCB).
Pharmacogenomics — Precision Medicine for India
Pharmacogenomics studies how genetic variation affects an individual's response to drugs — determining whether a drug will be effective, ineffective, or toxic for a given patient.
Why India Needs Its Own Pharmacogenomic Data
| Issue | Implication |
|---|---|
| Most drug dosage guidelines are based on European/Western genetic data | Standard doses may under- or over-medicate Indian patients |
| India has extreme internal genetic diversity (tribal, caste, linguistic groups) | A single "Indian average" is misleading |
| Known variant: CYP2C19 enzyme (metabolises clopidogrel, proton pump inhibitors) | Frequencies differ significantly between Indian communities and Western populations |
| TPMT variants affecting mercaptopurine metabolism | Relevant for childhood leukemia treatment in India |
GenomeIndia data will enable the construction of India-specific pharmacogenomic reference panels — a critical input for the shift to precision medicine.
Ayushman Bharat Digital Mission (ABDM)
Architecture
| Component | Detail |
|---|---|
| ABHA (Ayushman Bharat Health Account) | Unique 14-digit health ID; links all health records digitally; creation is voluntary |
| Health Facility Registry (HFR) | Registry of all hospitals, clinics, diagnostic centres |
| Healthcare Professionals Registry (HPR) | Registry of all licensed doctors, nurses, paramedics |
| Health Records | Patient health records linked to ABHA — accessible to patients and authorised providers |
Current Scale (as of February 2025)
| Metric | Figure |
|---|---|
| ABHA accounts created | ~74 crore (740 million+) |
| Health facilities registered (HFR) | ~3.63 lakh |
| Healthcare professionals registered (HPR) | ~5.64 lakh |
| Health records linked | ~49 crore |
Significance
- Enables continuity of care: a patient's records from a village health centre are accessible at a tertiary hospital.
- Reduces duplication of tests and paper records.
- Creates a data foundation for AI-driven diagnostics and epidemiological research.
- Interoperability framework aligns with global standards (FHIR — Fast Healthcare Interoperability Resources).
India's Pharma Exports — "Pharmacy of the World"
| Indicator | Data |
|---|---|
| Pharma exports FY 2024–25 | USD 30.47 billion (+9.4% YoY) |
| Pharma exports FY 2023–24 | USD 27.8–27.9 billion |
| Share of global generics (by volume) | Over 20% |
| Share of global vaccine demand | Over 60% |
| Export destinations | 200+ markets; USA (~34%), Europe (~19%) |
| Manufacturing units | 10,500+ units; 3,000+ companies |
| US FDA-approved plants outside USA | India has the highest number after the USA itself |
API Dependence on China — Strategic Vulnerability
| Parameter | Data |
|---|---|
| Share of India's bulk drug/API imports from China (FY24) | ~72% of overall bulk drug and intermediates imports |
| Antibiotic ingredient imports from China (by value, 2024) | ~87% |
| Absolute import value from China | USD 11.1 billion (2024) |
Policy response:
- PLI Scheme for Bulk Drugs (2020): Production-Linked Incentive scheme to promote domestic API manufacturing; ₹6,940 crore outlay.
- Bulk Drug Parks scheme: Three bulk drug parks being developed (Himachal Pradesh, Gujarat, Andhra Pradesh) with central funding.
National Biopharma Mission (NBM) — Innovate in India (i3)
| Parameter | Detail |
|---|---|
| Launched | Cabinet approval May 2017 |
| Budget | USD 250 million (~₹1,500 crore); 50% co-funded by World Bank |
| Implementing agency | DBT through BIRAC |
| Programme name | Innovate in India (i3) |
| Focus areas | Vaccines, biosimilars, medical devices, diagnostics |
| Goal | Create an enabling ecosystem for entrepreneurship and indigenous biopharmaceutical manufacturing |
| Infrastructure created | Bio-incubators, shared R&D facilities, technology transfer offices across India |
Clinical Trials — India as a Hub
India's strengths for clinical trials:
- Large, genetically diverse population with high disease burden — faster patient recruitment.
- Cost: Clinical trial costs 30–50% lower than in the US or Europe.
- Regulatory framework: CDSCO (Central Drugs Standard Control Organisation) under the Drugs and Cosmetics Act governs trial approvals.
CDSCO — India's Drug Regulator
| Parameter | Detail |
|---|---|
| Full form | Central Drugs Standard Control Organisation |
| Parent ministry | Ministry of Health and Family Welfare (under DGHS) |
| Head | Drug Controller General of India (DCGI) |
| Equivalent to | FDA (USA), EMA (Europe) |
| Key functions | Drug approval, clinical trial authorisation, quality standards for imports, vaccine and blood product licensing (jointly with State Drug Controllers) |
| HQ | FDA Bhawan, Kotla Road, New Delhi |
| Zonal offices | 6 zonal + 4 sub-zonal + 13 port offices + 7 laboratories |
ICMR Guidelines for Clinical Trials
ICMR's National Ethical Guidelines for Biomedical and Health Research Involving Human Participants (2017, revised) govern:
- Informed consent procedures.
- Compensation for trial-related injury.
- Special protections for vulnerable populations.
- Post-trial access to beneficial interventions.
Important: India amended the New Drugs and Clinical Trials Rules in 2019 — streamlined timelines, allowed academic clinical trials with reduced fees, and introduced provisions for orphan drugs and rare diseases.
Challenges in India's Health Biotech Sector
| Challenge | Detail |
|---|---|
| API dependence on China | ~72% of API imports from China — supply-chain risk exposed during COVID; policy response through PLI and Bulk Drug Parks |
| Regulatory capacity | CDSCO under-staffed relative to the volume of applications; delays affect innovation |
| IP vs. access tension | TRIPS flexibilities (compulsory licensing under Section 84, Patents Act) vs. attracting global pharma R&D investment |
| Cold-chain infrastructure | mRNA and some subunit vaccines require ultra-cold storage (−20°C to −70°C); rural cold-chain gaps remain |
| Clinical trial perception | Past controversies (2013 suspension of new trial approvals) damaged India's reputation; reforms since 2015 rebuilding confidence |
| Data governance for genomics | GenomeIndia data is 8 petabytes of sensitive genetic information; robust privacy and access frameworks (FeED protocol) are under development |
| Talent pipeline | Shortage of clinical pharmacologists, bioinformaticians, and regulatory scientists |
Quick Reference — Key Institutions, Schemes & Facts
| Item | Key Detail | Prelims/Mains Relevance |
|---|---|---|
| Serum Institute of India | World's largest vaccine manufacturer by volume; ~170 countries; 1.5B+ dose/year capacity | Prelims (vaccine facts) |
| Bharat Biotech | Covaxin (BBV152), ROTAVAC, Hillchol, JENVAC; 9B+ doses globally | Prelims + Mains |
| Biological E. Limited | Corbevax; est. 1953; first private biologics firm in India | Prelims |
| CERVAVAC | India's first qHPV vaccine; launched 24 Jan 2023 by SII; cervical cancer prevention | Prelims + Mains |
| Covaxin (BBV152) | Inactivated whole-virion; WHO EUL Nov 2021; ICMR–BBIL collaboration | Prelims + Mains |
| Corbevax | Protein subunit (RBD); WHO EUL; Texas Children's Hospital technology licensed to Biological E | Prelims |
| GenomeIndia | 10,074 whole genomes; 180M variants; Feb 2024 completion; IBDC Faridabad | Prelims + Mains |
| IBDC | Indian Biological Data Centre, Faridabad; set up by DBT at RCB | Prelims |
| ABHA | 14-digit unique health ID; ~740M+ accounts created (Feb 2025) | Prelims + Mains |
| ABDM | Launched 2021; digital health ecosystem; ABHA + HFR + HPR + linked health records | Mains |
| National Biopharma Mission | 2017; USD 250M (50% World Bank); BIRAC-managed; i3 programme | Prelims |
| PLI for Bulk Drugs | ₹6,940 crore; reduce API dependence on China | Mains |
| Pharma exports FY25 | USD 30.47 billion; 9.4% growth | Prelims |
| API dependence (China) | ~72% of bulk drug imports (FY24); 87% of antibiotic ingredients | Mains |
| CDSCO | National drug regulator; DCGI is head; under MoHFW | Prelims |
| mRNA vaccines | No DNA alteration; mRNA → cytoplasm → antigen → immune response; no nuclear entry | Prelims (conceptual) |
| Gennova saRNA platform | India's self-amplifying mRNA; HGCO19 (COVID-19); Nipah saRNA in development (CEPI funding) | Mains |
| Mission COVID Suraksha | DBT mission to fund indigenous COVID vaccine development | Prelims |
| Pharmacogenomics | Drug response varies by genetics; Indian population diversity requires India-specific panels | Mains |
Recent Developments (2024–2026)
India's Pharma Exports — $30.47 Billion in FY 2024–25
India's pharmaceutical exports reached $30.47 billion in FY 2024–25, registering 9.4% year-on-year growth — making India the world's third-largest pharmaceutical producer by volume and 14th by value. Formulations and biologics constitute 79.26% of exports; bulk drugs and drug intermediates account for 16.08%. The United States remains India's top destination (approximately 34% of exports), followed by Europe (approximately 19%).
India is the world's leading supplier of generic medicines, supplying approximately 20% of global generic drug volumes and 60% of WHO-essential medicines. The domestic pharmaceutical market reached approximately $60 billion in 2024, projected to grow to $130 billion by 2030. Key export growth drivers include biosimilars, specialty generics, and API (active pharmaceutical ingredient) supplies.
UPSC angle: India's pharma export value ($30.47 billion FY25), global rank (3rd by volume), US-Europe dependence, and biosimilars growth are Prelims and Mains data.
GenomeIndia Project — Human Genome Database 2024 Progress
The GenomeIndia Project (launched 2020 under DBT and CSIR) completed sequencing 10,000 genomes by February 27, 2024 — reaching its target ahead of the end-of-year deadline. The project covered 83 diverse population groups (Dravidian, Indo-Aryan, Tibeto-Burman, Austroasiatic communities). The dataset identified over 135 million genetic variations, including 27 million rare variants linked to diseases such as hypercholesterolemia, hypertrophic cardiomyopathy, and cancers — of which 7 million are novel (not found in global databases). Data is stored at the Indian Biological Data Centre (IBDC).
The data will enable: (a) pharmacogenomics panels specific to Indian populations (avoiding adverse drug reactions); (b) disease susceptibility mapping for Type 2 diabetes, tuberculosis, and cardiovascular diseases; (c) forensic applications; (d) population genomics for historical migration studies.
UPSC angle: GenomeIndia Project (10,000 genomes completed February 2024, 83 population groups, 135 million variations, IBDC), pharmacogenomics applications, and data governance are Prelims and Mains content.
Nipah Virus Response and mRNA Vaccine Development 2024
India's Kerala state managed Nipah virus outbreaks in 2018, 2019, 2021, and 2023. In 2024, DBT's Gennova Biopharmaceuticals developed a self-amplifying RNA (saRNA) Nipah vaccine candidate with CEPI (Coalition for Epidemic Preparedness Innovations) funding — advancing to Phase I clinical trials. This represents India's first mRNA/saRNA vaccine platform applied to a pathogen beyond COVID-19.
The CEPI-Gennova partnership exemplifies India's biotech sector's capacity to pivot from COVID-19 mRNA platform development to emerging infectious disease preparedness. CEPI's "100 Days Mission" — developing and deploying new vaccines in 100 days from pathogen identification — is supported by India's vaccine manufacturing capacity (Serum Institute alone can produce 1.5 billion doses/year).
UPSC angle: Nipah virus, saRNA vaccine platform, Gennova-CEPI partnership, India's 100-day vaccine mission preparedness, and Serum Institute's capacity are Prelims and Mains content.
